April Cashin-Garbutt

Natural Sciences

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year.

Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.

See less

Articles from April

Laser eye surgery: a glimpse into the future - An interview with Professor Dan Reinstein

LASIK (Laser In Situ Keratomileusis) creates a hinged flap with a microkeratome and evaporating corneal tissue under the flap with an excimer laser. However, the concept that refractive error could be corrected by sculpting corneal stromal tissue to change corneal curvature was the brainchild of Jose Ignacio Barraquer Moner in 1948.

9 Aug 2015

BRCA gene mutations and ovarian cancer: an interview with Dr Matulonis, Harvard Medical School

The BRCA gene encodes for the BRCA proteins, BRCA1 and BRCA2. These proteins are very important in repairing DNA, which they do by correcting double-stranded breaks.

2 Aug 2015

Does dandruff cause psychological distress? An interview with Dr Anjali Mahto

Dandruff is a common chronic scalp disorder that is characterised by flaking of the skin of the scalp. As skin cells die, they are shed from the scalp surface. For some people, however, excessive flaking occurs, resulting in dandruff.

28 Jul 2015

Voice cloning: an interview with Paul Welham, CEO, CereProc

CereVoice Me was essentially designed for those who had been diagnosed with MND/ALS and other illnesses that may cause an individual to lose the power of speech. CereProc identified that there was a gap in the market and pulled our resources together to build CereVoice Me, the goal of the service is to build a TTS voice efficiently and at a cost effective price.

27 Jul 2015

Multiple sclerosis relapse management: an interview with Gina Remington

MS relapses are typically reflective of new neurological symptoms. However, it can be a worsening of neurologic symptoms that begins after a patient has been stable (generally for about 30 days), but relapses are persistent and consistent changes in symptoms that occur for more than 24 to 48 hours.

26 Jul 2015

Current and new treatments for AMD: an interview with Dr Alan Cruess, AMD Alliance International

For two decades beginning in the late 1970’s through 2001, clinicians relied upon laser photocoagulation in the treatment of wet AMD caused by choroidal neovascularization. Attempts to obliterate the neovascular lesions often led to acute central visual loss and often, even with modest success, the lesions recurred with even more vision loss.

21 Jul 2015

Innovation in anaesthesia: an interview with Matti Lehtonen, GE Healthcare

The spectrum of patients seen today, from pre-term infants to the morbidly obese to the longer living elderly, is wider than ever before and increasingly more challenging with patients often presenting with multiple co-morbidities. This puts a huge strain on healthcare providers who are facing increasing challenges such as cost pressure and staff shortages.

14 Jul 2015

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

The main symptoms of advanced prostate cancer can include (but are not limited to) difficulty walking or climbing steps, unexplained pain, troubled sleep and taking pain relievers daily.

7 Jul 2015

Transitioning Infrared Imaging into Clinical Use

The CLIRSPEC network is a UK Engineering and Physical Sciences Research Council (EPSRC – EP/L012952/1) funded network in clinical infrared and Raman spectroscopy. Infrared and Raman spectroscopy can identify the hallmarks of disease and distinguish between diseased and non-diseased samples based upon inherent chemistry.

7 Jul 2015

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Since 2014, more than 16 million anti-malarial treatments derived from the Sanofi patented process for semi-synthetic artemisinin have been supplied to endemic countries in Africa.

28 Jun 2015